Ceptaz (Ceftazidime)


Glaxo Wellcome



Action And Clinical Pharmacology: In vitro studies indicate that the bactericidal action of ceftazidime, a semisynthetic cephalosporin antibiotic, results from inhibition of bacterial cell wall synthesis.

Ceftazidime has a high affinity for the Penicillin-Binding Protein-3 (PBP-3) and moderate affinity for the PBP-1a of certain gram negative organisms such as E. coli and P. aeruginosa. The affinity for PBP-1b is much less than that for either PBP-3 or PBP-1a. PBP-3 is involved in the process of cross-wall formation (septation). Binding to this protein results in formation of filaments and eventual death of the bacterium. PBP-1a and PBP-1b are involved in longitudinal wall synthesis (elongation) prior to septation. Binding to these proteins results in spheroplast formation followed by rapid lysis.

Ceftazidime has high affinity for PBP-1 and PBP-2 of S. aureus. However, the drug’s affinity for PBP-3 is very much less in this organism.

Indications And Clinical Uses: For the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases:

Lower Respiratory Tract Infections: Pneumonia caused by P. aeruginosa; H. influenzae including ampicillin-resistant strains; Klebsiella species; Enterobacter species; P. mirabilis; E. coli, Serratia species, S. pneumoniae, and S. aureus including ampicillin-resistant (but not methicillin-resistant) strains.

Urinary Tract Infections: Caused by P. aeruginosa; Enterobacter species; Proteus species (indole positive and negative); Klebsiella species, and E. coli.

Due to the nature of the underlying conditions which usually predispose patients to Pseudomonas infections of the lower respiratory and urinary tracts, a good clinical response accompanied by bacterial eradication may not be achieved despite evidence of in vitro sensitivity.

Skin Structure Infections: Caused by P. aeruginosa; Klebsiella species; E. coli; P. mirabilis; Enterobacter species; S. aureus, including ampicillin-resistant (but not methicillin-resistant) strains; and S. pyogenes.

Bacteremia/Septicemia: Caused by P. aeruginosa; Klebsiella species; E. coli; Serratia species; S. pneumoniae; S. aureus, including ampicillin-resistant (but not methicillin-resistant) strains; and S. epidermidis.

Bone Infections: Caused by P. aeruginosa; P. mirabilis; Enterobacter species; and S. aureus, including ampicillin-resistant (but not methicillin-resistant) strains.

Peritonitis: Caused by E. coli; Klebsiella species; and Peptostreptococcus species. Patients infected with Bacteroides species have also responded.

Meningitis: Caused by H. influenzae and N. meningitidis. Ceftazidime has also been used successfully in a limited number of cases of meningitis due to P. aeruginosa.

Specimens for bacteriologic culture should be obtained prior to therapy in order to identify the causative organisms and to determine their susceptibilities to ceftazidime. Therapy may be instituted before results of susceptibility testing are known. However, modification of the treatment may be required once these results become available.

Contra-Indications: Patients who have shown hypersensitivity to ceftazidime or the cephalosporin group of antibiotics. tag_WarningWarnings

Manufacturers’ Warnings In Clinical States: Before therapy with ceftazidime is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to ceftazidime, cephalosporins, penicillins, or other drugs. Ceftazidime should be administered with caution to any patient who has demonstrated some form of allergy, particularly to drugs. Ceftazidime should be given with caution to patients with Type 1 hypersensitivity reactions to penicillin. If an allergic reaction to ceftazidime occurs, treatment should be discontinued and standard agents (e.g. epinephrine, antihistamines, corticosteroids) administered as necessary.

Pseudomembranous colitis has been reported to be associated with treatment with ceftazidime (and other broad-spectrum antibiotics). Therefore, it is important to consider its diagnosis in patients administered ceftazidime who develop diarrhea. Treatment with broad-spectrum antibiotics, including ceftazidime, alters the normal flora of the colon and may permit overgrowth of Clostridia. Studies indicate that a toxin produced by C. difficile is one primary cause of antibiotic-associated colitis. Mild cases of colitis may respond to drug discontinuance alone. Moderate to severe cases should be managed with fluid, electrolyte, and protein supplementation as indicated. When the colitis is not relieved by discontinuance of ceftazidime administration or when it is severe, consideration should be given to the administration of vancomycin or other suitable therapy. Other possible causes of colitis should also be considered.

Precautions: Ceftazidime should be administered with caution to individuals with a history of gastrointestinal disease, particularly colitis.

Patients with impaired renal function (i.e. creatinine clearance of 50 mL/min/1.73 mor less) should be placed on the special dosage schedule for ceftazidime recommended in the Dosage section. Normal dosages in these individuals are likely to produce excessive serum concentrations of ceftazidime. Elevated levels of ceftazidime in these patients could lead to convulsions.

The concomitant administration of aminoglycosides and some cephalosporins has caused nephrotoxicity. Although transient elevations of BUN and serum creatinine have been observed in clinical studies, there is no evidence that ceftazidime, when administered alone, is significantly nephrotoxic. However, the effect of administering ceftazidime concomitantly with aminoglycosides is not known. Studies suggest that the concomitant use of potent diuretics such as furosemide and ethacrynic acid, may increase the risk of renal toxicity with cephalosporins.

Ceftazidime is eliminated via the kidneys, therefore the dosage should be reduced according to the degree of renal impairment.

Neurological sequelae have occasionally been reported when the dose has not been reduced appropriately (see Dosage in Impaired Renal Function).

Prolonged treatment with ceftazidime may result in the overgrowth of nonsusceptible organisms, including species originally sensitive to the drug. Repeated evaluation of the patient’s condition is essential. If superinfection occurs during therapy, appropriate measures should be taken.

Development of resistance during the administration of ceftazidime has been observed for S. aureus, members of the Enterobacteriaceae family, Acinetobacter species and Pseudomonas species.

Chloramphenicol is antagonistic in vitro with ceftazidime and other cephalosporins. The clinical relevance of this finding is unknown, but if concurrent administration of ceftazidime with chloramphenicol is proposed, the possibility of antagonism should be considered.

Pregnancy: The safety of ceftazidime in pregnancy has not been established. The use of ceftazidime in pregnant women requires that the likely benefit from the drug be weighed against the possible risk to the mother and fetus.

Reproduction studies have been performed in mice and rats employing ceftazidime doses of up to 25 times those usually administered to humans. These studies have revealed no evidence of impaired fertility or harm of the fetus caused by ceftazidime.

Animal reproduction studies, however, are not always predictive of human response.

Lactation: Ceftazidime is excreted in human milk in low concentrations (3.8 to 5.2 mg/L). The clinical significance of this is unknown, therefore, caution should be exercised when ceftazidime is administered to a nursing mother.

Children: The safety and efficacy of ceftazidime has not been established in infants (1 month of age or younger) and children (£12 years).

Geriatrics: The elimination of ceftazidime may be reduced due to impairment of renal function.

Drug-Laboratory Test Interactions : Ceftazidime may cause a false-positive reaction for glucose in the urine with copper reduction tests (Benedict’s or Fehling’s solution). As a false-negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase method be used to determine blood plasma glucose levels in patients receiving ceftazidime.

Ceftazidime does not interfere in the alkaline picrate assay for creatinine.

A positive Coombs’ test has been reported during treatment with cephalosporins. This phenomenon can interfere with cross matching of blood.

Adverse Reactions: The most common adverse effects have been local reactions following i.v. injection, allergic reactions and gastrointestinal reactions. Other adverse effects have been encountered less frequently.

Local (2.8% of patients): thrombophlebitis or phlebitis and pain with i.v. administration. Pain and/or inflammation after i.m. injection.

Hypersensitivity (2.7% of patients): pruritus, urticaria, allergic exanthema, and fever. There have been rare reports of toxic epidermal necrolysis. Angioedema and anaphylaxis including (bronchospasm and/or hypotension) have been reported very rarely.

Gastrointestinal (
Renal (
Hepatic (
Hematopoietic: eosinophilia (3.4%), positive Direct Coombs’ Test (5.1%), and with an incidence of
Miscellaneous (
Symptoms And Treatment Of Overdose: Symptoms and Treatment: Overdosage of cephalosporins can lead to neurological sequelae including encephalopathy, convulsions and coma. Excessive serum levels of ceftazidime can be reduced by hemodialysis or peritoneal dialysis. tag_DosageDosage

Dosage And Administration: Ceftazidime may be administered either i.v. or i.m. after reconstitution.

Dosage and route of administration should be determined by severity of infection, susceptibility of the causative organism(s) and condition of the patient. The i.v. route is preferable for patients with septicemia, peritonitis or other severe or life-threatening infections, or for patients who may be poor risks because of lowered resistance resulting from such debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure, or malignancy, particularly if shock is present or pending.

The usual duration of treatment is 7 to 14 days. For Streptococcal infections, therapy should be continued for at least 10 days.

Adults: The recommended daily dosage is 0.5 to 6 g administered in equally divided doses every 8 to 12 hours (see Table I).

For the treatment of infections caused by Staphylococcus species, a dosage of 1 or 2 g administered every 8 hours is recommended. For the treatment of infections (except those confined to the urinary tract) caused by Enterobacter species, a dosage of at least 1 g administered every 8 hours is recommended.

Geriatrics: In acutely ill elderly patients with reduced renal clearance of ceftazidime, the daily dosage should not exceed 3 g.

Children: The safety and efficacy of ceftazidime has not been established in infants (1 month of age or younger) and children (£12 years).

Impaired Hepatic Function: No adjustment in dosage is required for patients with hepatic dysfunction provided renal function is not impaired (see Pharmacology).

Adults with Impaired Renal Function: Ceftazidime is excreted almost exclusively by glomerular filtration. In patients in whom the glomerular filtration rate (GFR) is less than or equal to 50 mL/min (0.83 mL/s), the dosage of ceftazidime must be reduced to compensate for its slower excretion. After an initial loading dose of 1 g of ceftazidime, a maintenance dosage schedule should be followe.

Creatinine clearance (mL/s)= Weight (kg)x(140-age) 49xserum creatinine (mmol/L)

Creatinine clearance (mL/min)= Weight (kg)x(140-age) 72xserum creatinine (mg/dL)

Females: 0.85xabove value.

Mean serum half-life of ceftazidime in patients with no kidney function was reduced from a range of 24 to 35.4 hours between dialysis sessions to a range of 2.8 to 4.6 hours during hemodialysis. Therefore a loading dose of 1 g is recommended followed by 0.5 to 1 g after each hemodialysis period. Serum concentrations of ceftazidime should be carefully monitored and used as a basis to adjust the dosage.

Ceftazidime can also be used in patients undergoing peritoneal dialysis and continuous ambulatory peritoneal dialysis. In such patients, a loading dose of ceftazidime (1 g) is suggested, followed by 500 mg every 24 hours. Serum concentrations of ceftazidime should be carefully monitored and used as a basis to adjust the dosage.

Administration: I.M.: Ceftazidime may be administered by deep i.m. injection into a large muscle mass such as the upper outer quadrant of the gluteus maximus or vastus lateralis. The maximum dose of ceftazidime should be 1 g for a single i.m. injection.

Intermittent I.V. Administration: The reconstituted solution may be slowly injected into the vein over a period of 3 to 5 minutes or given through the tubing of an administration set. During the infusion of the solution containing ceftazidime, the administration of other solutions should be discontinued temporarily.

Continuous I.V. Infusion: Ceftazidime may also be administered over a longer period of time.

Note: If therapy with ceftazidime is carried out in combination with an aminoglycoside antibiotic, each should be administered at different sites because of a physical incompatibility. An aminoglycoside should not be mixed with ceftazidime in the same container.

Reconstitution: Note: Vials of ceftazidime as supplied are under a slightly reduced pressure. This may assist entry of the diluent. No gas relief needle is required when adding the diluent. No evolution of gas occurs on constitution. When the vial contents are dissolved, vials may still be under a reduced pressure. This reduced pressure is particularly noticeable for the 10 g pharmacy bulk package.

I.M. Use: Solutions for Reconstitution: Sterile Water for Injection, 0.5% w/v and 1% w/v Lignocaine Hydrochloride Injection, Bacteriostatic Water for Injection preserved with Benzyl Alcohol or Parabens.

Shake well until dissolved. The prepared solution may be further diluted to the desired volume with any of the solutions listed under “Solutions for I.V. Infusion”.

Direct I.V. Injection: Reconstitute as directed in Table IV.

Intermittent I.V. Infusion: Reconstitute as directed in Table IV for 1 g and 2 g vials of Ceptaz.

Continuous I.V. Infusion: 1 g and 2 g Vials: Reconstitute 1 g and 2 g vials of Ceptaz with 10 mL Sterile Water for Injection. The appropriate quantity of the reconstituted solution may be added to an i.v. bottle containing any of the solutions listed under “Solutions for I.V. Infusion”.

Pharmacy Bulk Vial: The availability of the pharmacy bulk vial is restricted to hospitals with a recognized i.v. admixture program.

Ceptaz for injection does not contain any preservatives. The pharmacy bulk vial is intended for multiple dispensing for i.v. use only, employing a single puncture. Reconstitute with 40 mL Sterile Water for Injection.

Shake well until dissolved. Following reconstitution with Sterile Water for Injection, the solution should be dispensed and diluted for use within 8 hours at room temperature (not exceeding 25°C). Any unused reconstituted solution should be discarded after 8 hours. The appropriate quantity of the reconstituted solution may be added to an i.v. bottle containing any of the solutions listed below.

Solutions for I.V. Infusion: 0.9% Sodium Chloride Injection, 1/6 Molar Sodium Lactate Injection, Ringers Injection USP, Lactated Ringers Injection USP, 5% Dextrose Injection, 5% Dextrose and 0.225% Sodium Chloride Injection, 5% Dextrose and 0.45% Sodium Chloride Injection, 5% Dextrose and 0.9% Sodium Chloride Injection, 10% Dextrose Injection, 10% Invert Sugar (Fructose/Dextrose) in Water for Injection, Normosol-M and 5% Dextrose Injection, Sterile Water for Injection.

Stability of Solutions: Storage: Reconstituted solutions should be administered within 12 hours when stored at room temperature (not exceeding 25°C), and within 72 hours when refrigerated, from the time of reconstitution, both when prepared as bolus injections, i.m. or i.v., and as infusion admixtures with recommended i.v. diluents.

Incompatibility: Ceftazidime should not be added to blood products, protein hydrolysates or amino acids. It should not be mixed together with an aminoglycoside. Ceftazidime is less stable in Sodium Bicarbonate Injection than in other i.v. fluids; therefore it is not recommended as a diluent.

Precipitation has been reported when vancomycin has been added to ceftazidime in solution. Therefore, it would be prudent to flush giving sets and i.v. lines between administration of these two agents.

Availability And Storage: I.M. or Direct I.V. Injection: Each vial contains: the equivalent of ceftazidime 1 g. Nonmedicinal ingredients: L-arginine. Packs of 10.

I.V. Injection or Infusion: Each vial contains: the equivalent of ceftazidime 1 and 2 g. Nonmedicinal ingredients: L-arginine. Packs of 10.

Each vial contains: the equivalent of ceftazidime 10 g. Nonmedicinal ingredients: L-arginine. Packs of 6.

Ceptaz in the dry state should be stored between 15 and 30°C protected from light.

CEPTAZ® Glaxo Wellcome Ceftazidime Antibiotic

Posted by

Connected Diseases :

Bacterial Meningitis

General Illness Information Common Name: Meningitis, Bacterial Medical Term: None Specified Description: Bacterial infection of the coverings of the brain and spinal cord (the meninges). …

Skin Care

Only healthy clean skin can perform its functions correctly. Proper skin care prevents skin diseases and premature aging. Types of skin diseases: In general, any…

Upper Respiratory Infection

General Illness Information Medical Term: Upper Respiratory Infection, URI Common name Common Cold Description: A contagious viral infection of the upper-respiratory passages Causes: Any of…

Genitourinary Disorders

Various diseases of the genitourinary system are most often associated with sexual infections and the prostate gland. Types: A brief list of diseases of the…